Estrogen sulfotransferase (SULT1E1) expression in benign and malignant human bone tumors

Svoboda, Martin; Thalhammer, Theresia; Aust, Sylvia; Arrich, Ferdi; Assadian, Ojan; Toma, Cyril D.

doi:10.1002/jso.20748

Cited by 6 publications

(5 citation statements)

References 39 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The human osteoblast outgrowth (hOB) cells from the explant culture were isolated from human cancellous bone obtained during orthopedic surgery (hip replacement), as described previously [20]. Cells were cultured in RPMI‐1640 medium with Glutamax (GibcoBRL, Paisley, UK) supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin G, 100 μ g/mL streptomycin and 0.5 μ g/mL amphotericin‐B.…”

Section: Methodsmentioning

confidence: 99%

Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors

Toma

Svoboda

Arrich

et al. 2007

Journal of Pineal Research

Self Cite

View full text Add to dashboard Cite

The beneficial effects of melatonin on bone homeostasis have been shown in various diseases. As this indoleamine causes dose-dependent modulation of bone-forming osteoblast and bone-resorbing osteoclast activities by receptor-independent and -dependent pathways, we investigated the expression of G-protein-coupled melatonin receptors (MTs) in malignant and non-malignant human bone lesions. By TaqMan polymerase chain reaction (PCR), we analyzed 30 specimens from osteosarcoma and 11 from benign bone tumors for MT1-mRNA expression. Furthermore, we determined mRNA expression levels of the osteoclast activity-stimulating receptor activator of nuclear factor-kappa B ligand (RANKL) and its counterpart osteoprotegerin (OPG). Although mean MT1-mRNA levels were similar (P = 0.596) in malignant (4.39 +/- 4.98-fold) and benign samples (4.64 +/- 6.81-fold), the highest MT1-mRNA levels (up to 27-fold) were observed in individual osteosarcomas, particularly, in two specimens of patients with local recurrence of the tumor. Moreover, mean RANKL- and OPG-mRNA levels were similar in malignant and benign specimens (RANKL: 7.38 +/- 9.61-fold versus 3.57 +/- 3.11-fold, P = 0.207; OPG: 23.45 +/- 32.76 versus 8.07 +/- 7.23-fold, P = 0.133). Again, highest RANKL- and OPG-mRNA levels (up to 41- and 160-fold, respectively) were observed in individual osteosarcomas. Expression of MT1-mRNA was confirmed in two human osteosarcoma cell lines (HOS, MG63). High expression levels of MT1-mRNA together with low OPG-mRNA were found in both osteosarcoma cell lines, while in normal human osteoblasts and bone marrow stromal cells, high OPG-mRNA levels were associated with low MT1-mRNA levels. These data on the abundant expression of MT1-mRNA in human bone tumors and osteosarcoma cells lines suggest an important role for MT1 in bone pathology.

show abstract

Section: Methodsmentioning

confidence: 99%

Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors

Toma

Svoboda

Arrich

et al. 2007

Journal of Pineal Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…From early ‘90s, various isotopic techniques demonstrated the presence of CYP19A1, 17βHSD reductive/oxidative, 3βHSD and STS activities and the mRNA expression of 17βHSD1, 2, 4, STS, SULT1E1, CYP19A1 and SDR5A in human osteoblastic (e.g., HOS, U20S, HTB-96 and MG63) and osteosarcoma cell lines like CRL-1543 (Purohit et al, 1992 ; Fujikawa et al, 1997 ; Jakob et al, 1997 ; Dong et al, 1998 ; Saito and Yanaihara, 1998 ; Janssen et al, 1999 ; Muir et al, 2004 ; Svoboda et al, 2007 ; Dias and Selcer, 2014 ).…”

Section: Intracrinology In Peripheral Tissuesmentioning

confidence: 99%

“…Additional intracrine imbalances are described in bone diseases, such as higher androgen reducing 17βHSD activity in benign vs. malignant tumors, declines of CYP19A1 from normal bone to osteosarcoma and expression of SULT1E1 in the majority of the skeletal benign and malignant lesions, originated in bones or from primary tumors elsewhere (Svoboda et al, 2007 ).…”

Section: Intracrinology In Peripheral Tissuesmentioning

confidence: 99%

Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery

et al. 2018

View full text Add to dashboard Cite

Our understanding of the intracrine (or local) regulation of estrogen and other steroid synthesis and degradation expanded in the last decades, also thanks to recent technological advances in chromatography mass-spectrometry. Estrogen responsive tissues and organs are not passive receivers of the pool of steroids present in the blood but they can actively modify the intra-tissue steroid concentrations. This allows fine-tuning the exposure of responsive tissues and organs to estrogens and other steroids in order to best respond to the physiological needs of each specific organ. Deviations in such intracrine control can lead to unbalanced steroid hormone exposure and disturbances. Through a systematic bibliographic search on the expression of the intracrine enzymes in various tissues, this review gives an up-to-date view of the intracrine estrogen metabolisms, and to a lesser extent that of progestogens and androgens, in the lower female genital tract, including the physiological control of endometrial functions, receptivity, menopausal status and related pathological conditions. An overview of the intracrine regulation in extra gynecological tissues such as the lungs, gastrointestinal tract, brain, colon and bone is given. Current therapeutic approaches aimed at interfering with these metabolisms and future perspectives are discussed.

show abstract

“…3A1. In bone cells, it is further metabolized to 17ß-estradiol (E2) by estrogenmetabolizing enzymes (26) providing the active estrogen. Furthermore, OATP2B1 also transports DHEAS, which is a precursor for E2.…”

Section: Discussionmentioning

confidence: 99%

Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts

Thalhammer¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. Organic anion transporting polypeptides (OATP) were identified as transmembrane transporters for various endo-and exogenous organic compounds (hormones, prostaglandins, anticancer drugs). OATP expression had been shown in different tissues, but not in bone tumors. Therefore, the expression pattern of all known eleven human OATPs was analyzed by quantitative RT-PCR in 21 human bone tumor specimens (osteosarcomas, bone metastases and benign aneurysmal bone cysts). Transcriptional expression of OATP1A2, 1C1, 2A1, 2B1, 3A1, 4A1, 4C1 and 5A1, but not of OATP1B1, 1B3 and 6A1 was observed in malignant and non-malignant tumor specimens at varying level. Importantly, OATP3A1, 4A1, 2B1 and 1C1 mRNA levels were significantly higher in aneurysmal bone cysts as compared to osteosarcomas. Elevated mRNA levels of OATP2A1, 1A2, and 4C1 in metastases from kidney cancer and of OATP5A1 in prostate cancer suggest that the OATP expression pattern in metastases is comparable to that of the primary tumors. Different to tissue, OATP expression in osteosarcoma cell lines HOS and MG-63, normal human osteoblast outgrowth cells (hOB) and bone marrow stromal cells (BMSC) is limited to OATP3A1 and OATP4A1. High OATP expression levels, particularly in benign bone tumors, suggest an important role of these transporters for providing hormones, their conjugates, prostaglandins and drugs in bone cells. Thereby, they may influence bone resorption and formation.

show abstract

Estrogen sulfotransferase (SULT1E1) expression in benign and malignant human bone tumors

Abstract: Frequent expression of SULT1E1 mRNA in various human bone tumors suggests that sulfonation might be important to control E2 levels and activity.

Cited by 6 publications

References 39 publications

Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors

Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors

Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery

Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts

Contact Info

Product

Resources

About